The effect of polypharmacy on quality of life in adult patients with nonalcoholic fatty liver disease in the United States

Background Nonalcoholic fatty liver disease (NAFLD) is a significant epidemiological problem with rising prevalence. Due to limited literature, the objective of this study is to examine the association between polypharmacy and health-related quality of life (QoL) in NAFLD adult patients. Methods A r...

Full description

Saved in:
Bibliographic Details
Published in:Quality of life research 2022-08, Vol.31 (8), p.2481-2491
Main Authors: Alrasheed, Marwan, Guo, Jeff Jianfei, Lin, Alex C., Wigle, Patricia R., Hardee, Angelica, Hincapie, Ana L.
Format: Article
Language:English
Subjects:
Adults
Generalized linear models
Liver diseases
Medicine
Medicine & Public Health
Polypharmacy
Public Health
Quality of life
Quality of Life Research
Sociology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Nonalcoholic fatty liver disease (NAFLD) is a significant epidemiological problem with rising prevalence. Due to limited literature, the objective of this study is to examine the association between polypharmacy and health-related quality of life (QoL) in NAFLD adult patients. Methods A retrospective observational study design was conducted to analyze health data collected by Steatohepatitis Clinical Research Network (NASH CRN). Patients were classified as receiving a polypharmacy therapy with five or more medications in their first screening visit. QoL was measured using the Short Form 36 (SF-36) instrument. Each patient self-reported the SF-36 form during the screening visit was compared between polypharmacy and non-polypharmacy groups using Wilcoxon Rank Sum test. Multivariable generalized linear models and multinomial logistic regression were performed to examine each predictor and its effect on QoL. Results Data included 1067 NAFLD adult patients; 834 patients used polypharmacy. The mean age was 48.64 years, and most patients were female (62%). Comparing NAFLD patients without steatohepatitis, borderline NASH, and definite NASH, the non-polypharmacy group had a significantly higher QoL than the polypharmacy group in Physical Component Summary (PCS) (86.25 vs 66.88, 85 vs 67.5, and 79.375 vs 63.12, respectively, all p  
ISSN:0962-9343
1573-2649
DOI:10.1007/s11136-022-03090-6